Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU

Novavax (NASDAQ:NVAX) said that it has officially transferred the marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi (NASDAQ:SNY) within the European Union. As a result of this transfer, Novavax received a milestone payment of $25M. This move allows Sanofi ...